INBRX-106
- Generic Name
- INBRX-106
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Elpiscience (Suzhou) Biopharma, Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06623136
- Locations
- ๐จ๐ณ
Taizhou Hospital, Taizhou, China
๐จ๐ณJilin Cancer Hospital, Changchun, Jilin, China
๐จ๐ณThe First Affiliated Hospital of He'nan University of Science and Technology, Luoyang, China
Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 12
- Registration Number
- NCT06353997
- Locations
- ๐บ๐ธ
Ellison Institute of Technology (EITM), Los Angeles, California, United States
๐บ๐ธProvidence Portland Cancer Institute - Franz Clinic, Portland, Oregon, United States
๐บ๐ธProvidence St. Vincent Medical Center, Portland, Oregon, United States
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPSโฅ20 HNSCC
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Interventions
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Inhibrx Biosciences, Inc
- Target Recruit Count
- 410
- Registration Number
- NCT06295731
- Locations
- ๐บ๐ธ
UC Davis, Sacramento, California, United States
๐ฆ๐บRoyal Adelaide Hospital, Adelaide, South Australia, Australia
๐ง๐ชUniversity Hospital Brussels, Jette, Belgium
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Elpiscience Biopharma, Ltd.
- Target Recruit Count
- 82
- Registration Number
- NCT04991506
- Locations
- ๐จ๐ณ
Jilin Cancer Hospital, Changchun, Jilin, China
A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Elpiscience Biopharma, Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04730843
- Locations
- ๐จ๐ณ
Jilin Cancer Hospital, Changchun, Jilin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.